On February 19, 2021 JHL Biotech, Inc., a global frontrunner in large-molecule biological drug development and manufacturing platform technologies, reported that it has changed its corporate name to Eden Biologics, Inc (Press release, JHL Biotech, FEB 19, 2021, View Source [SID1234635605]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The name change reflects the company’s continual commitment to producing affordable medicines for all patients in need and its evolving expertise in driving the innovations needed to shape the future of high-quality biologics development.

Please visit our new website at: www.edenbiologics.com

Eden Biologics will continue to fully operate in its current structure and all business contacts will remain unchanged.

"This is an exciting change for us and our evolving positioning effectively stamps our footprint as a global leader in the healthcare industry with focus on innovative therapeutics, which are needed now more than ever," said James Huang, Executive Chairman and CEO of Eden Biologics.

"We have developed numerous unique and expert competencies in-house, serving both our extensive Biologics Portfolio and our CDMO business. While our commitment to our Mission and Vision remains as strong as ever, we have an incredible ambition to grow and want Eden Biologics to become synonymous with the highest product quality and a pioneering technology platform for global biologics development."

The new name is effective immediately and has already been implemented across the company’s pipeline and services.